Posted by Michael Wonder on 21 Sep 2024
Astellas receives approval from the European Commission for Vyloy (zolbetuximab) in combination with chemotherapy for advanced gastric and gastro-oesophageal junction cancer
20 September 2024 - Treatment with the claudin 18.2 targeted monoclonal antibody shown to significantly extend both progression-free survival and overall survival in Phase 3 trials.
Astellas Pharma today announced that the European Commission has approved Vylov (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastro-oesophageal junction adenocarcinoma whose tumours are claudin 18.2 positive.
